Use/NN
of/IN
arsenic/JJ
trioxide/NN
(/(
As2O3/NN
)/)
in/IN
the/DT
treatment/NN
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
:/:
II/CD
./.
=====
Clinical/JJ
efficacy/NN
and/CC
pharmacokinetics/NNS
in/IN
relapsed/JJ
patients/NNS
./.

The/DT
therapeutic/JJ
effect/NN
of/IN
arsenic/JJ
trioxide/NN
(/(
As2O3/NN
)/)
in/IN
the/DT
treatment/NN
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
was/VBD
evaluated/VBN
among/IN
15/CD
APL/NN
patients/NNS
at/IN
relapse/NN
after/IN
all-trans/JJ
retinoic/JJ
acid/NN
(/(
ATRA/NN
)/)
induced/VBD
and/CC
chemotherapy/NN
maintained/VBD
complete/JJ
remission/NN
(/(
CR/NN
)/)
./.
=====
As2O3/NN
was/VBD
administered/VBN
intravenously/RB
at/IN
the/DT
dose/NN
of/IN
10/CD
mg/d/NN
./.
=====
Clinical/JJ
CR/NN
was/VBD
achieved/VBN
in/IN
nine/CD
of/IN
10/CD
(/(
90/CD
%/NN
)/)
patients/NNS
treated/VBN
with/IN
As2O3/NN
alone/RB
and/CC
in/IN
the/DT
remaining/VBG
five/CD
patients/NNS
treated/VBN
by/IN
the/DT
combination/NN
of/IN
As2O3/NN
and/CC
low-dose/JJ
chemotherapeutic/JJ
drugs/NNS
or/CC
ATRA/NN
./.
=====
During/IN
the/DT
treatment/NN
with/IN
As2O3/NN
,/,
there/EX
was/VBD
no/DT
bone/NN
marrow/NN
depression/NN
and/CC
only/RB
limited/JJ
side/JJ
effects/NNS
were/VBD
encountered/VBN
./.
=====
Pharmacokinetic/JJ
studies/NNS
,/,
which/WDT
were/VBD
performed/VBN
in/IN
eight/CD
patients/NNS
,/,
showed/VBD
that/IN
after/IN
a/DT
peak/JJ
level/NN
of/IN
5.54/CD
micromol/L/NN
to/TO
7.30/CD
micromol/L/NN
,/,
plasma/NN
arsenic/NN
was/VBD
rapidly/RB
eliminated/VBN
,/,
and/CC
the/DT
continuous/JJ
administration/NN
of/IN
As2O3/NN
did/VBD
not/RB
alter/VB
its/PRP$
pharmacokinetic/JJ
behaviors/NNS
./.
=====
In/IN
addition/NN
,/,
increased/VBN
amounts/NNS
of/IN
arsenic/NN
appeared/VBD
in/IN
the/DT
urine/NN
,/,
with/IN
a/DT
daily/JJ
excretion/NN
accounting/VBG
for/IN
approximately/RB
1/CD
%/NN
to/TO
8/CD
%/NN
of/IN
the/DT
total/JJ
daily/RB
dose/NN
administered/VBN
./.
=====
Arsenic/JJ
contents/NNS
in/IN
hair/NN
and/CC
nail/NN
were/VBD
increased/VBN
,/,
and/CC
the/DT
peak/JJ
content/NN
of/IN
arsenic/JJ
could/MD
reach/VB
2.5/CD
to/TO
2.7/CD
microg/g/NN
tissue/NN
at/IN
CR/NN
./.
=====
On/IN
the/DT
other/JJ
hand/NN
,/,
a/DT
decline/NN
of/IN
the/DT
arsenic/JJ
content/NN
in/IN
hair/NN
and/CC
nail/NN
was/VBD
observed/VBN
after/IN
withdrawal/NN
of/IN
the/DT
drug/NN
./.
=====
We/PRP
conclude/VBP
that/IN
As2O3/NN
treatment/NN
is/VBZ
an/DT
effective/JJ
and/CC
relatively/RB
safe/JJ
drug/NN
in/IN
APL/NN
patients/NNS
refractory/JJ
to/TO
ATRA/NN
and/CC
conventional/JJ
chemotherapy/NN
./.